ZNF692

Summary

ZNF692 (zinc finger protein 692, HGNC:26049) is a protein-coding gene on chromosome 1q44, encoding Zinc finger protein 692 (Q9BU19). May act as an transcriptional repressor for PCK1 gene expression, in turn may participate in the hepatic gluconeogenesis regulation through the activated AMPK signaling pathway.

Enables DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in negative regulation of transcription by RNA polymerase II and regulation of gluconeogenesis. Located in nucleolus and nucleoplasm.

Source: NCBI Gene 55657 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 108 total
• Druggable target: yes
• MANE Select transcript: NM_017865

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26049
Approved symbol	ZNF692
Name	zinc finger protein 692
Location	1q44
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20531, Zfp692, AREBP
Ensembl gene	ENSG00000171163
Ensembl biotype	protein_coding
OMIM	617758
Entrez	55657

Gene structure

Transcript identifiers

Ensembl transcripts: 45 — 20 protein_coding, 13 retained_intron, 9 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

ENST00000306601, ENST00000366471, ENST00000412341, ENST00000451251, ENST00000462037, ENST00000463519, ENST00000468455, ENST00000470787, ENST00000474351, ENST00000476503, ENST00000477070, ENST00000478107, ENST00000482023, ENST00000483223, ENST00000483791, ENST00000491971, ENST00000495731, ENST00000496053, ENST00000496231, ENST00000496411, ENST00000497847, ENST00000528141, ENST00000530699, ENST00000530986, ENST00000533614, ENST00000533647, ENST00000533927, ENST00000533976, ENST00000534456, ENST00000534660, ENST00000869876, ENST00000869877, ENST00000869878, ENST00000869879, ENST00000869880, ENST00000869881, ENST00000914625, ENST00000914626, ENST00000914627, ENST00000914628, ENST00000964808, ENST00000964809, ENST00000964810, ENST00000964811, ENST00000964812

RefSeq mRNA: 5 — MANE Select: NM_017865 NM_001136036, NM_001193328, NM_001350072, NM_001350073, NM_017865

CCDS: CCDS31127, CCDS44348, CCDS53487

Canonical transcript exons

ENST00000306601 — 12 exons

Exon	Start	End
ENSE00003458663	248850682	248850781
ENSE00003482959	248855725	248855946
ENSE00003516149	248856288	248856422
ENSE00003530734	248853937	248854051
ENSE00003532525	248855380	248855458
ENSE00003580912	248856514	248856562
ENSE00003586914	248858131	248858321
ENSE00003640499	248857234	248857497
ENSE00003679011	248855558	248855635
ENSE00003692227	248857828	248857859
ENSE00003899341	248850008	248850516
ENSE00003899450	248858918	248859085

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 98.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.1503 / max 129.7001, expressed in 1722 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
18533	6.0130	1638
18532	1.7417	960
18531	1.0071	567
18534	0.3731	165
18530	0.0154	2

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	98.13	gold quality
right uterine tube	UBERON:0001302	97.92	gold quality
cerebellar hemisphere	UBERON:0002245	97.90	gold quality
cerebellar cortex	UBERON:0002129	97.79	gold quality
lower esophagus mucosa	UBERON:0035834	97.75	gold quality
cerebellum	UBERON:0002037	96.69	gold quality
right frontal lobe	UBERON:0002810	96.30	gold quality
left testis	UBERON:0004533	96.25	gold quality
adenohypophysis	UBERON:0002196	96.20	gold quality
right testis	UBERON:0004534	96.20	gold quality
right lobe of thyroid gland	UBERON:0001119	96.06	gold quality
pituitary gland	UBERON:0000007	95.73	gold quality
apex of heart	UBERON:0002098	95.60	gold quality
endocervix	UBERON:0000458	95.55	gold quality
body of pancreas	UBERON:0001150	95.33	gold quality
left lobe of thyroid gland	UBERON:0001120	95.31	gold quality
body of uterus	UBERON:0009853	95.27	gold quality
granulocyte	CL:0000094	95.11	gold quality
right ovary	UBERON:0002118	95.11	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.04	gold quality
left ovary	UBERON:0002119	94.95	gold quality
mucosa of transverse colon	UBERON:0004991	94.92	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.92	gold quality
minor salivary gland	UBERON:0001830	94.81	gold quality
sural nerve	UBERON:0015488	94.71	gold quality
ectocervix	UBERON:0012249	94.63	gold quality
cingulate cortex	UBERON:0003027	94.48	gold quality
anterior cingulate cortex	UBERON:0009835	94.48	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.46	gold quality
left uterine tube	UBERON:0001303	94.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.73

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
PCK1	Repression

JASPAR motifs

Motif	Name	Family
MA1986.1	ZNF692	More than 3 adjacent zinc fingers
MA1986.2	ZNF692	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:25690854

miRNA regulators (miRDB)

18 targeting ZNF692, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4646-3P	98.65	66.98	693
HSA-MIR-4799-3P	97.78	65.97	893
HSA-MIR-3144-5P	97.64	65.45	646
HSA-MIR-4720-5P	97.46	65.67	893
HSA-MIR-5588-5P	97.46	65.70	913
HSA-MIR-4448	97.04	66.22	752
HSA-MIR-6772-3P	97.04	65.89	784
HSA-MIR-2355-3P	96.84	68.54	909
HSA-MIR-6856-3P	96.47	66.27	781

Literature-anchored findings (GeneRIF, showing 8)

• cloning and characterization of a novel zinc finger transcription factor referred to as AREBP. AREBP is phosphorylated at Ser(470) by AMPK. (PMID:17097062)
• The results show that ZNF692 is expressed in LUAD tissues compared to adjacent normal tissues, and hyper-expression of ZNF692 in LUAD is an independent risk factor for worse overall survival in LUAD patients (HR: 8.800, 95%CI: 1.082-71.560, P = 0.042) by Tissue Microarray stain assay (TMA). (PMID:28669730)
• ZNF692 promotes CC cells proliferation and invasion through suppressing p27(kip1) transcription by directly binding its promoter region. (PMID:30466806)
• Results found that ZNF692 was upregulated in colon adenocarcinoma (COAD) tissues and cells and that high ZNF692 expression was significantly correlated with lymph node metastasis, distant metastasis and tumor stage in COAD patients. Furthermore, ZNF692 promoted COAD cell proliferation, migration and invasion via the PI3K/AKT pathway, suggesting that ZNF692 may serve as a novel oncogene for COAD. (PMID:30816443)
• Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma. (PMID:37980166)
• ZNF692 promotes cell proliferation, invasion and migration of human prostate cancer cells by targeting the EMT signaling pathway. (PMID:38291502)
• ZNF692 regulates nucleolar morphology by interacting with NPM1 and modifying its self-assembly properties. (PMID:38382671)
• ZNF692 promotes osteosarcoma cell proliferation, migration, and invasion through TNK2-mediated activation of the MEK/ERK pathway. (PMID:38650011)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp692	ENSMUSG00000037243
rattus_norvegicus	Zfp692	ENSRNOG00000002682

Paralogs (36): ZBTB32 (ENSG00000011590), SNAI2 (ENSG00000019549), PRDM1 (ENSG00000057657), PRDM6 (ENSG00000061455), ZNF76 (ENSG00000065029), PATZ1 (ENSG00000100105), MAZ (ENSG00000103495), ZBTB16 (ENSG00000109906), ZNF451 (ENSG00000112200), ZBTB45 (ENSG00000119574), ZNF410 (ENSG00000119725), SNAI1 (ENSG00000124216), ZNF384 (ENSG00000126746), ZBTB1 (ENSG00000126804), VEZF1 (ENSG00000136451), PRDM14 (ENSG00000147596), ZNF276 (ENSG00000158805), ZNF362 (ENSG00000160094), ZNF653 (ENSG00000161914), ZNF281 (ENSG00000162702), ZNF148 (ENSG00000163848), ZNF143 (ENSG00000166478), HIC2 (ENSG00000169635), PRDM10 (ENSG00000170325), ZNF296 (ENSG00000170684), ZNF575 (ENSG00000176472), HIC1 (ENSG00000177374), ZBTB18 (ENSG00000179456), ZBTB42 (ENSG00000179627), ZBTB20 (ENSG00000181722), ZBTB7C (ENSG00000184828), SNAI3 (ENSG00000185669), ZFP91 (ENSG00000186660), MTF1 (ENSG00000188786), SCRT2 (ENSG00000215397), SCRT1 (ENSG00000261678)

Protein

Protein identifiers

Zinc finger protein 692 — Q9BU19 (reviewed: Q9BU19)

Alternative names: AICAR responsive element binding protein

All UniProt accessions (8): E7ET73, E9PLQ5, E9PLQ7, E9PRH5, Q9BU19, H0YCH4, H0YDF5, H0YEY1

UniProt curated annotations — full annotation on UniProt →

Function. May act as an transcriptional repressor for PCK1 gene expression, in turn may participate in the hepatic gluconeogenesis regulation through the activated AMPK signaling pathway.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous. Highly expressed in brain, thymus and spleen.

Post-translational modifications. Phosphorylation at Ser-470 results in loss of DNA-binding activity.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9BU19-1	1	yes
Q9BU19-2	2
Q9BU19-3	3
Q9BU19-4	4
Q9BU19-5	5

RefSeq proteins (5): NP_001129508, NP_001180257, NP_001337001, NP_001337002, NP_060335* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050888	ZnF_C2H2-type_TF	Family

Pfam: PF00096

UniProt features (49 total): compositionally biased region 7, mutagenesis site 6, strand 6, zinc finger region 5, splice variant 5, turn 5, helix 5, modified residue 3, sequence conflict 3, region of interest 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6H0G	X-RAY DIFFRACTION	4.25
2D9H	SOLUTION NMR
2DLK	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BU19-F1	54.32	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 162, 231, 470

Mutagenesis-validated functional residues (6):

Position	Phenotype
62	does not affect phosphorylation by ampk.
63	does not affect phosphorylation by ampk.
386	does not affect phosphorylation by ampk.
402	does not affect phosphorylation by ampk.
442	does not affect phosphorylation by ampk.
470	reduces phosphorylation by ampk. does not affect dna binding. does not repress transcription of pck1.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 111 (showing top): GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_MONOSACCHARIDE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_REGULATION_OF_GLUCOSE_METABOLIC_PROCESS, GOBP_GLUCOSE_METABOLIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_BIOSYNTHETIC_PROCESS, GOBP_MONOSACCHARIDE_METABOLIC_PROCESS, chr1q44, CUI_TCF21_TARGETS_2_UP, GOBP_REGULATION_OF_GLUCONEOGENESIS, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, GOCC_NUCLEOLUS, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of gluconeogenesis (GO:0006111), regulation of transcription by RNA polymerase II (GO:0006357), regulation of macromolecule metabolic process (GO:0060255), regulation of primary metabolic process (GO:0080090)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleoplasm (GO:0005654), nucleolus (GO:0005730), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
regulation of metabolic process	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
nuclear lumen	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
gluconeogenesis	1
regulation of glucose metabolic process	1
regulation of carbohydrate biosynthetic process	1
macromolecule metabolic process	1
primary metabolic process	1
cis-regulatory region sequence-specific DNA binding	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
cellular anatomical structure	1
intracellular membraneless organelle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

946 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF692	HNRNPD	P07029	626
ZNF692	CRBN	Q96SW2	609
ZNF692	KHSRP	Q92945	597
ZNF692	ELAVL1	Q15717	580
ZNF692	ZFP36	P26651	573
ZNF692	RNF166	Q96A37	550
ZNF692	DDX6	P26196	453
ZNF692	TIAL1	Q01085	447
ZNF692	CENPA	P49450	446
ZNF692	GON4L	Q3T8J9	438
ZNF692	ZFP36L1	Q07352	435
ZNF692	TIA1	P31483	417
ZNF692	UQCC1	Q9NVA1	404
ZNF692	ZNF827	Q17R98	401
ZNF692	FXR1	P51114	400

IntAct

11 interactions, top by confidence:

A	B	Type	Score
KAT5	ZNF692	psi-mi:“MI:0915”(physical association)	0.560
STAT2	INPPL1	psi-mi:“MI:0914”(association)	0.530
NPM1	RPS3A	psi-mi:“MI:0914”(association)	0.350
ZNF692	NSD2	psi-mi:“MI:0914”(association)	0.350
ZNF692	IFI30	psi-mi:“MI:0914”(association)	0.350
ZNF692	HIBADH	psi-mi:“MI:0914”(association)	0.350
CDC25B	ZNF692	psi-mi:“MI:0914”(association)	0.350
ZNF692	U2SURP	psi-mi:“MI:0914”(association)	0.350
KAT5	ZNF692	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (65): ZNF692 (Affinity Capture-MS), RPS26P11 (Affinity Capture-MS), KBTBD8 (Affinity Capture-MS), RAD18 (Affinity Capture-MS), NSD1 (Affinity Capture-MS), FBXO11 (Affinity Capture-MS), HIBADH (Affinity Capture-MS), MGA (Affinity Capture-MS), POLR1E (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), RPL26L1 (Affinity Capture-MS), SPTY2D1 (Affinity Capture-MS), IMP4 (Affinity Capture-MS), WHSC1 (Affinity Capture-MS), DDX24 (Affinity Capture-MS)

ESM2 similar proteins: A0JNJ4, A2APT9, A6NEL2, A6NP61, B1ASB6, B1WBS3, B2RXF5, F6WEQ6, O15015, O43918, O88282, O88286, O95785, P98168, P98169, Q2M3G4, Q2MHN3, Q2QGD7, Q3U1J1, Q3U381, Q497V6, Q5SW24, Q5SXM2, Q6YND2, Q6ZMQ8, Q6ZMY3, Q7TN08, Q7TSX9, Q80SU3, Q80YE4, Q811H0, Q8BG26, Q8BZW2, Q8C8V1, Q8IX07, Q8IY92, Q8N143, Q8N1G0, Q8NC74, Q8TBE0

Diamond homologs: A0JNJ4, F6WEQ6, Q3U381, Q62511, Q96JP5, Q9BU19, Q6YND2, Q96CK0

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
ZNF692	“down-regulates quantity by repression”	PCK1	“transcriptional regulation”
PRKAA1	down-regulates	ZNF692	phosphorylation
AMPK	down-regulates	ZNF692	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

108 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1982 predictions. Top by Δscore:

Variant	Effect	Δscore
1:248850514:CAC:C	acceptor_gain	1.0000
1:248850681:CTG:C	donor_gain	1.0000
1:248853936:CCA:C	donor_gain	1.0000
1:248854050:TG:T	acceptor_gain	1.0000
1:248855391:G:GA	donor_gain	1.0000
1:248855942:CACTA:C	acceptor_gain	1.0000
1:248855944:CTA:C	acceptor_gain	1.0000
1:248855945:TA:T	acceptor_gain	1.0000
1:248855945:TACTG:T	acceptor_loss	1.0000
1:248855946:ACTGA:A	acceptor_loss	1.0000
1:248855947:C:A	acceptor_loss	1.0000
1:248855947:C:CC	acceptor_gain	1.0000
1:248855948:T:C	acceptor_loss	1.0000
1:248856270:C:CA	donor_gain	1.0000
1:248858182:T:TA	donor_gain	1.0000
1:248850512:CACAC:C	acceptor_gain	0.9900
1:248850517:C:CG	acceptor_loss	0.9900
1:248850524:C:CT	acceptor_gain	0.9900
1:248850525:A:T	acceptor_gain	0.9900
1:248850530:C:CT	acceptor_gain	0.9900
1:248850681:CTGCA:C	donor_gain	0.9900
1:248850782:C:CC	acceptor_gain	0.9900
1:248853932:CTCA:C	donor_loss	0.9900
1:248853933:TCACC:T	donor_loss	0.9900
1:248853934:C:CG	donor_loss	0.9900
1:248853935:A:AC	donor_gain	0.9900
1:248853936:C:CC	donor_gain	0.9900
1:248854047:TGGTG:T	acceptor_gain	0.9900
1:248854048:GGTG:G	acceptor_gain	0.9900
1:248854050:TGCTA:T	acceptor_loss	0.9900

AlphaMissense

3374 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:248850741:G:C	F398L	1.000
1:248850741:G:T	F398L	1.000
1:248850743:A:G	F398L	1.000
1:248850467:G:C	H435D	0.999
1:248850498:A:C	F424L	0.999
1:248850498:A:T	F424L	0.999
1:248850500:A:G	F424L	0.999
1:248850515:A:G	C419R	0.999
1:248850702:G:C	H411Q	0.999
1:248850702:G:T	H411Q	0.999
1:248850704:G:C	H411D	0.999
1:248850709:C:G	R409P	0.999
1:248850716:G:C	H407D	0.999
1:248850724:A:G	L404P	0.999
1:248850742:A:G	F398S	0.999
1:248850753:G:C	C394W	0.999
1:248850754:C:T	C394Y	0.999
1:248850755:A:G	C394R	0.999
1:248850764:A:G	C391R	0.999
1:248853953:G:C	H379Q	0.999
1:248853953:G:T	H379Q	0.999
1:248853963:A:G	L376P	0.999
1:248853974:A:C	F372L	0.999
1:248853974:A:T	F372L	0.999
1:248853976:A:G	F372L	0.999
1:248853980:G:C	F370L	0.999
1:248853980:G:T	F370L	0.999
1:248853982:A:G	F370L	0.999
1:248854009:A:G	C361R	0.999
1:248855401:G:C	F339L	0.999

dbSNP variants (sampled 300 via entrez): RS1000226515 (1:248852938 G>A), RS1000342818 (1:248858991 A>T), RS1000451652 (1:248851928 C>A), RS1000855712 (1:248858883 G>A), RS1002031902 (1:248850576 G>A), RS1002103742 (1:248856607 G>C), RS1002116825 (1:248852004 G>A,C), RS1002178502 (1:248858360 C>G,T), RS1002192623 (1:248853386 C>T), RS1002433419 (1:248857033 T>C), RS1002693018 (1:248853421 C>T), RS1002766164 (1:248859214 C>T), RS1002792640 (1:248854807 G>C,T), RS1002848206 (1:248860235 T>C), RS1002871794 (1:248853595 A>T)

Disease associations

OMIM: gene MIM:617758 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009560_3	Decreased low contrast letter acuity in multiple sclerosis	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008385	visual acuity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4879533 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol S	affects cotreatment, decreases expression, decreases methylation	2
(+)-JQ1 compound	decreases expression	2
Valproic Acid	decreases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
bisphenol F	affects cotreatment, decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
lead acetate	decreases expression	1
trichostatin A	affects expression	1
sodium arsenite	decreases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
jinfukang	affects cotreatment, increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Caffeine	increases phosphorylation	1
Cisplatin	increases expression, affects cotreatment	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Polychlorinated Biphenyls	affects expression	1
Selenium	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Thalidomide	decreases expression, increases degradation	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Vincristine	decreases expression	1
Vitamin E	affects cotreatment, decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4822142	Binding	Protac activity at CRBN/ZNF692 in human Kelly cells assessed as induction of ZNF692 degradation by measuring downregulation of ZNF692 protein expression at 1 uM measured after 5 hrs by proteomics analysis based LC-MS analysis	A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. — Eur J Med Chem

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LX	Abcam HeLa ZNF692 KO	Cancer cell line	Female
CVCL_XW76	HEK293 eGFP-ZNF692	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.